

Gene therapy project

30/10/23

1 slide/group

Title

General Idea

Aim

Gene therapy project

Theme I: Aging

Group A: Bernardi, Ilie, Colonnelli, Bastianelli

Charcot marie tooth – pmp22

Group B: Hazrati, Bartolini, Glaudo, Montrone, Pourali

Spastic paraplegias 3a – at11

Theme II: Cancer

Group C: Belvedere, Jeong, Majaliwa, Virgilio

Retinoblastoma – rb1

Group D: Santacroce, Pace, Serra, Fanelli, Duarte

Hepatic cancer – RACGAP1


Gene therapy project

Mail to: mattia.latorre@uniroma1.it

Cc: Isabella.saggio@uniroma1.it

Cancer

Group D: Santacroce, Pace, Serra, Fanelli, Duarte
Hepatic cancer – RACGAP1



RACGAP1 competitive inhibition in hepatocellular carcinoma via vector based mRNA transfection

Lavinia Pace


Antonio Duarte

Ernest Serra


Miriana Santacroce

Luigi Fanelli






RACGAP1 3D structure
via Uniprot



RACGAP1 phosphorylation activation
cascade

<https://www.nature.com/articles/s41388-022-02274-1#Sec13>



Cancer

Group C: Belvedere, Jeong, Majaliwa, Virgilio

Retinoblastoma – rb1


Prime editing of Rb1 gene as an innovative therapeutical strategy for retinoblastoma treatment

Background:

- Retinoblastoma is the most common type of eye cancer in children associated with the mutation in the RB1 gene.
- Every form of retinoblastoma (familial and sporadic) has the Rb1 gene mutated to some extent.
- Rb1 gene is located on chromosome 13, it consists of 27 exons.

Aim of the project: to develop a tool to prevent and cure the retinoblastoma onset

Strategy: design a pegRNA able to target a specific point mutation and stimulate the DNA repair systems.



Aging

Group B: Hazrati, Bartolini, Glaudo, Montrone, Pourali
Spastic paraplegias 3a – atl1




SAPIENZA
UNIVERSITÀ DI ROMA

Correcting
Atlastin 1 (ATL-1)
abnormal activity in
Spastic paraplegia 3A
(SPG3A)

by providing a functional version of the
mutated gene with homologous
recombination

Montrone, Glaudo, Hazrati, Pourali, Bartolini



Aging


Group B: Hazrati, Bartolini, Glaudo, Montrone, Pourali *Spastic paraplegias 3a – at11*

Background - Spastic paraplegia 3A

- ❖ The **pure hereditary spastic paraplegias (HSPs)** are a group of conditions in which there is a progressive length-dependent degeneration of the distal ends of the corticospinal tract axons, resulting in spastic paralysis of the legs.
- ❖ **Autosomal dominant spastic paraplegia-3A (SPG3A)** is caused by heterozygous mutation in the *ATL1* gene on chromosome 14q22. These lead to an abnormal activity of atlastin-1, which impairs the functioning of neurons.
- ❖ The *ATL1* gene encodes **atlastin-1**, a dynamin-related GTPase, which plays a role in formation of the tubular endoplasmic reticulum (ER) network and in axon elongation in neurons.



dimerization



(Xin Bian et al., Structures of the atlastin GTPase provide insight into homotypic fusion of endoplasmic reticulum membranes, 2011)

Aging

Group A: Bernardi, Ilie, Colonnelli, Bastianelli

Charcot marie tooth – pmp22

Silencing of PMP22 promoter 2 using a
CRISPR/Cas9 combined with
methyltransferase (DNMT3A) in CMT1A

Aging

Group A: Bernardi, Ilie, Colonnelli, Bastianelli

Charcot marie tooth – pmp22

Does an epigenetic modification, at the level of PMP22 promoter 2, restore physiological phenotype of the SC?

- Overexpression of PMP22 protein overloads the protein folding apparatus in Schwann cells and activates the unfolded protein response. This leads to Schwann cell apoptosis, dys- and de- myelination and secondary axonal degeneration, ultimately causing neurological disabilities.
- CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of PMP22 promoter 2.
- **EXPECTED:** restore of the physiological phenotype in SC and consequently the recovery of neuromuscular function.

Aging

Group A: Bernardi, Ilie, Colonnelli, Bastianelli

Charcot marie tooth – pmp22

Silencing of P2X7 using a CRISPR/Cas9
combined with methyltransferase
(DNMT3A) in CMT1A

Aging

Group A: Bernardi, Ilie, Colonnelli, Bastianelli

Charcot marie tooth – pmp22

Could inhibition of P2X7 gene restore the physiological phenotype of SC?

- High levels of intracellular $[Ca^{2+}]$ have been linked to the overexpression of the P2X7 purinoceptor/ion channel typical of CMT1A SCs. It has been reported that high intracellular Ca^{2+} led to the inhibition of SC maturation and differentiation, as well as inhibiting the expression and compaction of the myelin protein.
- CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of P2X7
- EXPECTE: The inhibition of P2X7 causes a decrease in intracellular $[Ca^{2+}]$ and restore the physiological phenotype of SC